The Journal of arthroplasty · 2025
Increased Body Mass Index Is Associated With Increased Cost for Primary Total Hip Arthroplasty Irrespective of Complications or Readmissions.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Akwuole Frances, Rumalla Kranti C, Sontag-Milobsky Isaac L, Chen Austin R, Riccobono Giancarlo, Edelstein Adam I
Аннотация
BACKGROUND: Surgeons participating in alternative payment models may encounter financial disincentives in caring for patients whose care requires higher costs for the treatment facility. While smaller studies have shown a positive relationship between body mass index (BMI) and cost in total hip arthroplasty (THA), this question has yet to be examined using data in a nationally representative dataset. We sought to leverage a national dataset to assess the relationship between BMI and cost in THA.
METHODS: We queried a health care dataset from 2016 to 2022 to identify primary THAs using Current Procedural Terminology and International Classification of Disease-Procedure Coding System codes (27130, 0SR90xx, and 0SRB0xx) with a corresponding osteoarthritis diagnosis (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM): M16). Patient demographics, characteristics, and cost variables were extracted directly from the dataset. Cost was defined by supplies, labor, and equipment and assessed over a 90-day period starting with the index surgical encounter. A multivariate generalized linear model estimated costs across eight BMI categories (World Health Organization BMI categories, with BMI > 40 patients grouped into BMI 40 to 45, BMI 45 to 50, and BMI > 50). A linear regression model assessed the effect of BMI on costs. Both models controlled for age, sex, payer, race, the Elixhauser comorbidity index, and ethnicity.
RESULTS: This study examined 10,366 primary THAs completed from 2016 to 2022. The mean BMI was 30.0 (standard error [SE] ± 0.1), the mean index cost was $14,632 (SE 52.9), and the mean 90-day cost was $16,527 (SE 145.4). Index and 90-day costs were lowest in the BMI 25 to 30 cohort ($14,344 and $15,865) and highest for the BMI >50 cohort ($17,503 and $28,281), respectively. On multivariate analyses, index and 90-day cost increased by $23 and $69, respectively, for every one-point increase in BMI (P < 0.001).
CONCLUSIONS: Results from this nationally representative dataset demonstrate that increasing BMI is associated with increased index and 90-day costs for THA. This information may be useful to stakeholders in the development of alternative payment models.
METHODS: We queried a health care dataset from 2016 to 2022 to identify primary THAs using Current Procedural Terminology and International Classification of Disease-Procedure Coding System codes (27130, 0SR90xx, and 0SRB0xx) with a corresponding osteoarthritis diagnosis (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM): M16). Patient demographics, characteristics, and cost variables were extracted directly from the dataset. Cost was defined by supplies, labor, and equipment and assessed over a 90-day period starting with the index surgical encounter. A multivariate generalized linear model estimated costs across eight BMI categories (World Health Organization BMI categories, with BMI > 40 patients grouped into BMI 40 to 45, BMI 45 to 50, and BMI > 50). A linear regression model assessed the effect of BMI on costs. Both models controlled for age, sex, payer, race, the Elixhauser comorbidity index, and ethnicity.
RESULTS: This study examined 10,366 primary THAs completed from 2016 to 2022. The mean BMI was 30.0 (standard error [SE] ± 0.1), the mean index cost was $14,632 (SE 52.9), and the mean 90-day cost was $16,527 (SE 145.4). Index and 90-day costs were lowest in the BMI 25 to 30 cohort ($14,344 and $15,865) and highest for the BMI >50 cohort ($17,503 and $28,281), respectively. On multivariate analyses, index and 90-day cost increased by $23 and $69, respectively, for every one-point increase in BMI (P < 0.001).
CONCLUSIONS: Results from this nationally representative dataset demonstrate that increasing BMI is associated with increased index and 90-day costs for THA. This information may be useful to stakeholders in the development of alternative payment models.